Active Ingredient(s): Miltefosine
FDA Approved: * March 19, 2014
Category: Antiprotozoal / Anthelmintic

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Impavido Overview

Miltefosine, sold under the trade name Impavido among others, is a medication mainly used to treat leishmaniasis and free-living amoeba infections such as Naegleria fowleri and Balamuthia mandrillaris.[2] This includes the three forms of leishmaniasis: cutaneous, visceral and mucosal.[3] It may be used with liposomal amphotericin B or paromomycin.[4] It is taken by mouth.[3] Common side effects include vomiting, abdominal pain, f...

Read more Impavido Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Impavido Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Impavido: (2 results)

Sorted by National Drug Code
  • 61744-050 Impavido 50 mg Oral Capsule by Paladin Therapeutics Inc.
  • 69051-300 Impavido 50 mg Oral Capsule by Profounda, Inc.

Other drugs which contain Miltefosine or a similar ingredient: (2 results)